AstraZeneca India to Launch Datverzo as Q2 Revenue Rises 30%
Article excerpt
Highlighted: the sentence this signal was extracted from
AstraZeneca Pharma India Limited will launch Datverzo (datopotamab deruxtecan), a targeted therapy for advanced HR-positive, HER2-negative breast cancer, in India in November 2026, the company told stock exchanges on 7 November 2026. The update came two days after the drugmaker reported a 30.4% rise in Q2 FY27 revenue to ₹729 crore. In its exchange intimation, the company said the Drugs Controller General of India (DCGI) granted Datverzo import and market permission in Form CT-20, which it had disclosed on 17 December 2025. Commercial launch will now follow this month. Datverzo is approved for adults with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (IHC 0, IHC 1+ or IHC 2+/ISH-negative) who have already received endocrine-based therapy and chemotherapy for advanced disease. The filing did not disclose pricing. The launch adds to an active period for oncology pricing in India. Trade margin caps on 137 anti-cancer drugs take effect on 9 November, as covered in our report on cancer drug price cuts saving ₹3,502 crore a year. The company announced its results for the July–September 2026 quarter on 5 November 2026: The company said growth came from its oncology, biopharmaceuticals and rare disease portfolios. Results also included exceptional items linked to the closure of its Bengaluru...
Keep reading with a free account
The rest of this article, and every signal for AstraZeneca, is in your free account.
